Pharma News

Drugmakers are seeking to limit their reliance on Chinese contractors who produce drugs used in clinical trials and early-stage manufacturing, a move that is benefiting rivals in India, according to interviews with 10 industry executives and experts.

Scientists at St. Jude Childrens Research Hospital showed that GRP78 is a promising, but complex, target for CAR T-cell immunotherapy for brain and solid tumors.

In Alzheimer’s disease and related dementias, cognitive decline is driven by the overaccumulation of a normal brain protein known as tau. Wherever tau builds up, nearby brain tissue starts to degenerate and die. 

The research environment at UiT The Arctic University of Norway has found a bacteriocin that can help inhibit the growth of antibiotic-resistant bacteria. "An exciting discovery", says researcher Runa Wolden at the Department of Clinical Medicine.

Treating cancer is becoming increasingly complex, but also offers more and more possibilities. After all, the better a tumor’s biology and genetic features are understood, the more treatment approaches there are. To be able to offer patients personalized therapies tailored to their disease, laborious and time-consuming analysis and interpretation of various data is required.

Scientists have developed an ingestible device that can safely monitor vital signs like breathing and heart rate from inside humans. The tool, described November 17 in the journal Device, has the potential to provide accessible and convenient care for people at risk of opioid overdose.

Cell Biology Lab was inaugurated at Kumar Organic Products Research Centre on 15th November 2023 by Prof. Dr. Samir K Brahmachari , Former Director General, CSIR.

Biocon Biologics Limited a subsidiary of Biocon Ltd. has announced that MHRA, Medicines and Healthcare products Regulatory Agency in the UK, has granted marketing authorization for YESAFILI®, a biosimilar of Aflibercept.

In September, YESAFILI®, received marketing authorization approval from the European Commission (EC) for the European Union (EU).

Sage Therapeutics has priced the oral postpartum depression medicine at USD 15,900 for a full 14-day course of treatment which is developed with Biogen. The pricing of medicine has been announced recently, whereas the drug was approved by the FDA in August.